Please assess the completion status of the following clinical trial:

Trial Title: As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of mild persistent asthma as defined by NHLBI/WHO 97; for at least 6 months;~* FEV1 ³ 75% of predicted normal value;~* Positive response to the reversibility test to b2 agonist, defined as an increase \> 12% in the FEV1 measured 30 minutes following 2 puffs (2x100mg) of inhaled Salbutamol spray, or positive methacholine challenge (PC20\<8mg/ml or PD20\<1 mg) within the previous 6 months;~* Stable asthma. Asthma is defined stable if none of the following occurred during the last 14 days of the run-in period: diurnal variation of more than 20% in PEF on 2 consecutive days; use of four or more inhalations of b2 agonist per day on two consecutive days; need the use of oral corticosteroids;~Exclusion Criteria:~* COPD as defined by the ERS - Consensus Statement;~* Patients with more than 10 packs/year of cigarettes history and current smokers;~* History of near fatal asthma and/or admission in intensive care unit because of asthma;~* One severe exacerbation during the run-in period;~* Three or more courses of oral corticosteroids or hospitalisation for asthma during the previous 1 year;~* Patients treated with more than 500 mcg/day of beclomethasone or equivalent for more than 6 months in the previous last year;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).